New In-Body CAR-T therapy targets tough blood cancers
NCT ID NCT07511426
First seen Apr 21, 2026 · Last updated May 22, 2026 · Updated 8 times
Summary
This study tests a new treatment called U96 for people with B-cell leukemia or lymphoma that has come back or not responded to standard therapy. U96 is a type of CAR-T therapy that works inside the body to help the immune system attack cancer cells. The main goals are to check if it is safe and to see how well it works. About 30 to 48 adults will take part, and they will be followed for up to 15 years to monitor long-term effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B CELL LEUKEMIA AND LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.